Facultad de Medicina (FM)
Centro académico
Emory University
Atlanta, Estados UnidosPublicaciones en colaboración con investigadores/as de Emory University (24)
2024
-
AI is a viable alternative to high throughput screening: a 318-target study
Scientific Reports, Vol. 14, Núm. 1
-
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387
-
Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)
Scientific Reports
-
Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma
Future Oncology, Vol. 20, Núm. 18, pp. 1221-1235
-
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma
Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152
-
Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries
Heart and Lung, Vol. 68, pp. 131-144
2023
-
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
New England Journal of Medicine, Vol. 388, Núm. 11, pp. 1002-1014
2022
-
Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis
Critical Care, Vol. 26, Núm. 1
-
Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021
Journal of Translational Medicine, Vol. 20, Núm. 1
2021
-
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design
Future Oncology, Vol. 17, Núm. 16, pp. 1987-2003
-
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
Journal of Hepatology, Vol. 75, Núm. 3, pp. 600-609
2020
-
A roadmap for the development of ivermectin as a complementary malaria vector control tool
American Journal of Tropical Medicine and Hygiene, Vol. 102, pp. 3-24
-
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
The Lancet Oncology, Vol. 21, Núm. 2, pp. 207-221
-
Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial
JAMA Oncology
2019
-
Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [ 18 F]FDG: version 1.0
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 46, Núm. 3, pp. 540-557
-
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
Blood, Vol. 134, Núm. 5, pp. 421-431
-
Paternal preconception folate intake in relation to gestational age at delivery and birthweight of newborns conceived through assisted reproduction
Reproductive BioMedicine Online, Vol. 39, Núm. 5, pp. 835-843
2018
-
Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and spectri phase 3 randomized clinical trials
JAMA Ophthalmology, Vol. 136, Núm. 6, pp. 666-677
-
Treatable inherited rare movement disorders
Movement Disorders, Vol. 33, Núm. 1, pp. 21-35
2017
-
Recent progress in translational research on neurovascular and neurodegenerative disorders
Restorative Neurology and Neuroscience, Vol. 35, Núm. 1, pp. 87-103